Collegium Pharmaceutical (COLL) Expected to Announce Earnings on Thursday

Key Points

• Collegium Pharmaceutical is expected to announce its Q2 2025 earnings on August 7th, with analysts predicting earnings of $1.88 per share and revenue of $182.26 million.
• The company recently authorized a stock buyback plan to repurchase up to $150 million worth of shares, which signals confidence in the company's valuation.
• Collegium's stock has a current market cap of $986.39 million and a 52-week stock price range between $23.23 and $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $1.88 per share and revenue of $182.26 million for the quarter. Collegium Pharmaceutical has set its FY 2025 guidance at EPS.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). The company had revenue of $177.76 million during the quarter, compared to the consensus estimate of $174.96 million. Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The firm's quarterly revenue was up 22.7% compared to the same quarter last year. During the same period last year, the business earned $1.45 EPS. On average, analysts expect Collegium Pharmaceutical to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL traded up $0.21 during mid-day trading on Friday, reaching $30.07. 445,406 shares of the company traded hands, compared to its average volume of 358,050. The company's 50 day moving average price is $30.48 and its 200-day moving average price is $29.71. The firm has a market cap of $966.15 million, a PE ratio of 24.65 and a beta of 0.64. Collegium Pharmaceutical has a 52 week low of $23.23 and a 52 week high of $42.29. The company has a debt-to-equity ratio of 3.30, a current ratio of 1.08 and a quick ratio of 1.01.

Collegium Pharmaceutical declared that its board has authorized a share buyback program on Monday, July 7th that permits the company to repurchase $150.00 million in shares. This repurchase authorization permits the specialty pharmaceutical company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of Collegium Pharmaceutical stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $30.62, for a total value of $202,122.62. Following the sale, the director owned 70,658 shares of the company's stock, valued at $2,163,547.96. The trade was a 8.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 2.51% of the company's stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Collegium Pharmaceutical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company's stock worth $569,000 after acquiring an additional 825 shares during the last quarter. Millennium Management LLC increased its stake in Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company's stock worth $19,338,000 after acquiring an additional 461,914 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Collegium Pharmaceutical by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company's stock worth $2,120,000 after acquiring an additional 4,625 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in Collegium Pharmaceutical by 218.7% during the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company's stock worth $3,926,000 after acquiring an additional 90,255 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently commented on COLL shares. Needham & Company LLC restated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Wall Street Zen cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 5th. Finally, Piper Sandler restated a "neutral" rating and set a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.75.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.